Bioactive Silver Nanoparticles Coated with Curcumin Inhibit Angiogenesis through MMP-9 and Cox-2 Down-Regulation

Area of Science:

• Nanomedicine
• Cancer Therapy
• Bioconjugation

Background:

• Angiogenesis inhibition is a key cancer therapy strategy.
• Curcumin and silver nanoparticles (AgNPs) possess anti-angiogenic properties.
• Poor curcumin solubility and AgNP side effects limit their therapeutic efficacy.

Purpose of the Study:

• To develop curcumin-coated silver nanoparticles (Cur-AgNPs) to enhance anti-angiogenic activity.
• To improve curcumin's aqueous solubility and mitigate AgNP toxicity.
• To evaluate the in vitro and in vivo anti-angiogenic potential of Cur-AgNPs.

Main Methods:

• Cur-AgNPs were synthesized using curcumin as a reducing and stabilizing agent.
• In vitro anti-angiogenesis was assessed using Human Umbilical Vein Endothelial Cells (HUVECs).
• In vivo anti-angiogenesis was evaluated using the Chorioallantoic Membrane (CAM) assay.

Main Results:

• Cur-AgNPs exhibited an average diameter of 39 nm with spherical morphology.
• In vitro studies showed Cur-AgNPs inhibited HUVEC viability (IC50 = 13 μg/ml) and induced apoptosis.
• Cur-AgNPs significantly reduced angiogenesis in the CAM model, decreasing vessel number, length, and hemoglobin content.

Conclusions:

• Curcumin conjugation with AgNPs offers a promising strategy to enhance the therapeutic potential of both agents.
• Cur-AgNPs demonstrate significant in vitro and in vivo anti-angiogenic activity.
• Further research on the safety and biocompatibility of Cur-AgNPs is warranted.